Reply  by Poulter, Neil R. et al.
5E
R
A
P
A
B
(
f
H
t
e
a
t
t
o
a
F

a
w
s
e
w
w
A
n
f
(
s
b
a
w
w
v
t
m
a
A
i
s
m
o
s
a
o
m
a
i
t
o
b
l
o
t
m
*
*
U
v
3
I
E
R
1
2
3
R
D
d
a
p
a
B
P
w
p
a
b
o
p
W
c
t
a
I
H
p
A
H
C
H
h
e
C
p
931JACC Vol. 55, No. 9, 2010 Correspondence
March 2, 2010:926–33. Benson K, Hartz AJ. A comparison of observational studies and
randomized, controlled trials. N Engl J Med 2000;342:1878–86.
levated Heart
ate in Hypertension
Target for Treatment?
oulter et al. (1) recently reported some interesting data from the
SCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial–
lood Pressure Lowering Arm) study showing that heart rate
HR) reduction with atenolol was not beneficial in patients with
ast HR. When subjects were divided into 5 categories of baseline
R, there was no attenuation of the superior impact of allocation
o amlodipine-based compared with atenolol-based therapy on
vent rates among the patients with higher baseline HRs. The
uthors are to be commended for their interesting analysis, but
heir interpretation of results does not seem to be appropriate. In
he ASCOT-BPLA study, baseline HR was not predictive of
utcome, and there was not even a tendency for higher HRs to be
ssociated with increased rate of cardiovascular events. From
igure 1 in their article (1), it appears that the subjects with an HR
90 beats/min had an even lower rate of events than subjects with
n HR 60 beats/min in both treatment groups (1). Thus, if HR
as not a risk factor for cardiovascular disease, it comes as no
urprise that a reduction in HR had no effect on cardiovascular
vents. However, the results of ASCOT-BPLA are in contrast
ith those of most studies performed in general populations and
ith all previous studies performed in hypertensive patients (2).
mong the 22,192 hypertensive patients in the INVEST (INter-
ational VErapamil-SR/trandolapril STudy), both baseline and
ollow-up HRs were potent independent predictors of outcome
3). The authors of the ASCOT-BPLA study should thus provide
ome explanation for the lack of predictive capacity shown by the
aseline HR in their study. One possible explanation may be that,
t variance with most studies, HR in the ASCOT-BPLA study
as measured with a semiautomatic device. This method is fraught
ith problems because blood pressure-measuring devices are not
alidated for measuring HR, and readings may be influenced by
he occurrence of artifacts. In addition, it is known that HR
easured with automatic monitors elicits a smaller alarm reaction
nd is not equivalent to HR measured by a doctor or a nurse (2).
nother crucial problem is that in the ASCOT-BPLA study, the
mpact of final HR on outcome was not tested. In the INVEST
tudy, when both baseline and follow-up HRs were included in the
odels, only follow-up HR remained a significant predictor of
utcome (3). According to the authors of the ASCOT-BPLA
tudy, “there was some suggestion that HR at 6 weeks was
ssociated with nonfatal myocardial infarction and fatal CHD
utcome” (1), but these important results were not shown. This
ight indicate that a low final achieved HR (lower on atenolol)
ctually had a favorable effect on cardiovascular outcomes as it did
n the INVEST study. To explore this possibility, we encourage
he ASCOT-BPLA investigators to analyze the predictive power
f final HR in their sample. It is possible that atenolol exerts a
eneficial effect on the cardiovascular system due to the HR-
owering action and a detrimental one due to its untoward effects wn several metabolic variables and central BP. Controlled clinical
rials performed with third-generation beta-blockers may shed
ore light on this controversial issue.
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eply
r. Palatini misquotes our findings in his first sentence in that we
o not mention the effects of heart rate (HR) reduction in our
rticle (1). However, he then correctly describes our findings by
ointing out that baseline HR did not affect the superiority of
mlodipine-based versus atenolol-based therapy in the ASCOT-
PLA (Anglo-Scandinavian Cardiac Outcomes Trial–Blood
ressure Lowering Arm). He further misrepresents our findings
hen he says that in the ASCOT-BPLA “baseline HR was not
redictive of outcome.” In fact, we reported that it predicted
ll-cause, noncardiovascular, and cardiovascular (CV) mortality,
ut not nonfatal CV events. These findings are compatible with
ur statement that “Baseline HR has been reported as a significant
redictor of various CV outcomes in some but not all studies” (1).
e believe that the data regarding predictability of HR are less
onsistent than Dr. Palatini suggests, as witnessed by the study
hat we referenced (2) and a more recent publication (3). We
cknowledge that in studies of secondary prevention (e.g., the
NVEST [INternational VErapamil-SR/trandolapril STudy]) (4),
R is a more consistent predictor of cardiovascular outcomes, but
atients with coronary heart disease were excluded from the
SCOT study.
We are unaware of any published data describing “problems” of
R measurement using semiautomatic blood pressure devices.
We are urged to report the association between “final HR” and
V outcomes. We briefly reported that associations with attained
R at 6 weeks post-randomization (almost all in-trial HR changes
ad occurred by then) were apparent with coronary but not other
nd points. In an earlier publication, we reported the impact on
V events of the “final” and accumulated mean levels of various
arameters including HR (5). In general, accumulated mean levels
ere better predictors of CV events. Higher HR was apparently
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March 2, 2010:926–33eneficial in terms of CV outcomes, but this was presumably
onfounded by the disadvantages of the atenolol-based regimen.
However, we did not focus on the variable predictability of HR
ecause that was not the purpose of the study. We wanted to know
hether having a higher baseline HR attenuated the superior
ffects on major CV events of the amlodipine-based compared
ith atenolol-based regimen. We could find no evidence of any
uch attenuation, and hence we believe that an increased baseline
R should not be an indication for preferential use of beta-
lockade in hypertensive populations without coronary heart dis-
ase. Even if baseline HR had not predicted CV outcomes in the
SCOT study, we believe that the same conclusion should be
rawn.
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leeding Risk on
arfarin Among Elderly
atients With Atrial Fibrillation
oli et al. (1) observed different rates of major hemorrhage between
atients younger than 80 years of age and 80 years of age and older.
s discussed by the authors, these rates differed considerably from
he rates of major hemorrhage observed among similarly aged
ohorts by Hylek et al. (2). We want to highlight an important
ethodological issue in the authors’ calculation of event rates. The puthors state, “the overall exposure to warfarin for each patient was
alculated in relation to aging, before and after his/her 80th
irthday.” Thus, the authors allowed crossover of prevalent war-
arin survivors from the younger cohort to the age 80 years
nception cohort. At the time of enrollment, the baseline age 80
ears cohort numbered 180 patients. Yet, in Table 1 of their article
1), the authors provide baseline characteristics for 327 patients in
he age 80 years group. The 2 age inception cohorts are distinct
nd should contribute person-years exclusively to their baseline
ssignment. Given this methodological error, the rates of hemor-
hage provided for the 2 inception cohorts are flawed. The reader
s also unable to compare baseline characteristics between the
ounger and age 80 years inception cohorts because the authors
ermitted crossover of 157 patients. In addition, the observation
eriod in the study by Hylek et al. (2) was intentionally truncated
t 1 year to provide the first-year experience on warfarin. Calcu-
ation of adverse event rates over years tends to enrich the
erson-year denominator with “survivors” because bleeding rates
re highest in the first 90 days of warfarin therapy. To accurately
eport rates of major hemorrhage among elderly individuals newly
tarting warfarin, the authors need to recalculate the bleeding rates
ccording to baseline group assignment without crossover between
he groups. To enable comparison of the 2 studies, events and
erson-years of observation would need to be restricted to the
atients’ first year of therapy. The anticipated results would be
igher bleeding rates and deterioration of time “in-range” as
eported.
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eply
e studied a cohort of atrial fibrillation patients on oral antico-
gulant treatment for stroke prophylaxis (1). Our patients were
outinely followed by the Anticoagulation Clinic of our institution
ith a median follow-up of 2.7 years, and some of them for as long
s 13 years. At the beginning of warfarin treatment, the mean age
f our cohort was 75 years; therefore, many patients reached the
ge of 80 years during follow-up. As stated in the article, we
ecided to analyze the occurrence of adverse events in relation to
ging to evaluate whether aging itself could be correlated with an
ncrease in bleeding risk that exceeds the advantages of stroke
revention. In reporting clinical characteristics of patients, we
